Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

References

• GroesslEJLiuLSklarMTallySRKaplanRMGaniatsTGMeasuring the impact of cataract surgery on generic and vision-specific quality of lifeQual Life Res20132261405141423015266
   PubMed Web of Science ®Google Scholar
• BuchHVindingTLa CourMAppleyardMJensenGBNielsenNVPrevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye StudyOphthalmology20041111536114711714
   PubMed Web of Science ®Google Scholar
• [no authors listed]Vision 2020: the cataract challengeCommunity Eye Health20001334171917491949
   PubMedGoogle Scholar
• CongdonNO’ColmainBKlaverCCCauses and prevalence of visual impairment among adults in the United StatesArch Ophthalmol2004122447748515078664
   PubMed Web of Science ®Google Scholar
• MonnetDTépenierLBrézinAPObjective assessment of inflammation after cataract surgery: comparison of 3 similar intraocular lens modelsJ Cataract Refract Surg200935467768119304088
   PubMed Web of Science ®Google Scholar
• Prolensa [package insert]Tampa, FLBausch and Lomb Inc2013
   Google Scholar
• www.ema.europa.eu [homepage on the Internet]Nevanac (nepafenac)European Medicines Agency2014 [updated September 18, 2013]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000818/human_med_000928.jspandmid=WC0b01ac058001d124Accessed March 25, 2014
   Google Scholar
• Ilevro [package insert]Fort Worth, TXAlcon Laboratories Inc2013
   Google Scholar
• DonnenfeldEDPerryHDWittpennJRSolomonRNattisAChouTPreoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curveJ Cataract Refract Surg20063291474148216931258
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Cataract and Anterior Segment PanelPreferred Practice Patterns: Cataract in the Adult EyeSan FranciscoAmerican Academy of Ophthalmology2011
   Google Scholar
• WarnerTDMitchellJACyclooxygenases: new forms, new inhibitors, and lessons from the clinicFASEB J200418779080415117884
   PubMed Web of Science ®Google Scholar
• FindlORedefining the treatment paradigm for post-operative inflammation control – the role of topical non-steroidal anti-inflammatory drugsEuro Ophthalmol Rev2010415459
   Google Scholar
• ColinJThe role of NSAIDs in the management of postoperative ophthalmic inflammationDrugs20076791291130817547472
   PubMed Web of Science ®Google Scholar
• CsukasSPatersonCABrownKBhattacherjeePTime course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxinInvest Ophthalmol Vis Sci19903123823872154416
   PubMed Web of Science ®Google Scholar
• KoayPThe emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmologyBr J Ophthalmol19968054804858695573
   PubMed Web of Science ®Google Scholar
• WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
   PubMed Web of Science ®Google Scholar
• RenfroLSnowJSOcular effects of topical and systemic steroidsDermatol Clin19921035055121617809
   PubMed Web of Science ®Google Scholar
• BeckerBThe side effects of corticosteroidsInvest Ophthalmol19643549249714229934
   PubMedGoogle Scholar
• McGheeCNPharmacokinetics of ophthalmic corticosteroidsBr J Ophthalmol199276116816841477046
   PubMed Web of Science ®Google Scholar
• BartlettJDHorwitzBLaibovitzRHowesJFIntraocular pressure response to loteprednol etabonate in known steroid respondersJ Ocul Pharmacol1993921571658345288
   PubMedGoogle Scholar
• O’BrienTPEmerging guidelines for use of NSAID therapy to optimize cataract surgery patient careCurr Med Res Opin20052171131113716004683
   PubMed Web of Science ®Google Scholar
• CableMComparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single siteClin Ophthalmol20126997100422815642
   PubMedGoogle Scholar
• EndoNKatoSHaruyamaKShojiMKitanoSEfficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetesActa Ophthalmol201088889690019725815
   PubMed Web of Science ®Google Scholar
• WarrenKABahraniHFoxJENSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edemaRetina201030226026620175270
   PubMed Web of Science ®Google Scholar
• SinghRAlpernLJaffeGJEvaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathyClin Ophthalmol201261259126922927737
   PubMedGoogle Scholar
• WangQWYaoKXuWBromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsificationOphthalmologica2013229418719423429038
   PubMed Web of Science ®Google Scholar
• AhujaMDhakeASSharmaSKMajumdarDKTopical ocular delivery of NSAIDsAAPS J200810222924118437583
   PubMed Web of Science ®Google Scholar
• ChoHWolfKJWolfEJManagement of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solutionClin Ophthalmol2009319921019668566
   PubMedGoogle Scholar
• DonnenfeldEDHollandEJStewartRHGowJAGrilloneLRBromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammationOphthalmology200711491653166217445902
   PubMed Web of Science ®Google Scholar
• HendersonBAGaytonJLChandlerSPGowJAKlierSMMcNamaraTRSafety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and painOphthalmology2011118112120212721762992
   PubMed Web of Science ®Google Scholar
• RidgwayDAnalgesics for acute pain: meeting the United States Food and Drug Administration’s requirements for proof of efficacyClin J Pain200420312313215100587
   PubMed Web of Science ®Google Scholar
• SilversteinSMCableMGSadriEOnce daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and painCurr Med Res Opin20112791693170321751945
   PubMed Web of Science ®Google Scholar
• MiyakeKOgawaTTajikaTGowJAMcNamaraTROcular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humorJ Ocul Pharmacol Ther200824657357819049295
   PubMed Web of Science ®Google Scholar
• MukaiKMatsushimaHGotohNEfficacy of ophthalmic nonsteroidal anti-inflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacificationJ Cataract Refract Surg20093591614161819683162
   PubMed Web of Science ®Google Scholar
• Bromday [package insert]Irvine, CAISTA Pharmaceuticals, Inc2011
   Google Scholar
• BrownHBTaylorPMuscarinic receptor agonists and antagonistsHardmanJGLimbirdLEMolinoffPBRuddonRWGoodman and Gilman’s The Pharmacological Basis of Therapeutics9th edNew YorkMcGraw-Hill1996
   Google Scholar
• SancilioLFNolanJCWagnerLEWardJWThe analgesic and anti-inflammatory activity and pharmacologic properties of bromfenacArzneimittelforschung19873755135193497637
   PubMed Web of Science ®Google Scholar
• WalshDAMoranHWShambleeDAAnti-inflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analoguesJ Med Chem19842711137913886436487
   PubMed Web of Science ®Google Scholar
• KidaTOgawaTMcNamaraTREvaluation of the Human COX-2 Inhibition of Amfenac, Bromfenac, Diclofenac, and KetorolacSan DiegoAmerican Society of Cataract and Refractive Surgery2007
   Google Scholar
• RuizJLópezMMilàJLozoyaELozanoJJPouplanaRQSAR and conformational analysis of the anti-inflammatory agent amfenac and analoguesJ Comput Aided Mol Des1993721831988320556
   PubMed Web of Science ®Google Scholar
• BaklayanGAPattersonHMSongCKGowJAMcNamaraTR24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbitsJ Ocul Pharmacol Ther200824439239818665811
   PubMed Web of Science ®Google Scholar
• Bronuck [package insert]Osaka, JapanSenju Pharmaceutical Co2009
   Google Scholar
• Xibrom [package insert]Irvine, CAISTA Pharmaceuticals, Inc2010
   Google Scholar
• WaltersTRGoldbergDFPeaceJHGowJABromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trialsOphthalmology20141211253324021896
   PubMed Web of Science ®Google Scholar
• GowJABoyceJDReiserHJBerryRDaoJTChandlerSPRandomized, placebo-controlled, integrated phase III clinical trials of a once daily, low-concentration, modified bromfenac ophthalmic solution following cataract surgery: focus on zero to trace anterior chamber inflammationPoster presented at: Annual Meeting of the Association for Research in Vision and OphthalmologyMay 5; 2013Seattle, WA
   Google Scholar
• JonesJFrancisPOphthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agentExpert Opin Pharmacother200910142379238519735215
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDDonnenfeldAGlobal experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drugInt Ophthalmol Clin2006464214017060789
   PubMedGoogle Scholar
• DuongHQWestfieldKCSingletonICComparing the efficacy of bromfenac 0.09% and nepafenac 0.1% post cataract surgery: a prospective evaluationJ Clinic Experiment Ophthalmol201128177
   Google Scholar
• OkekeCOQuigleyHAJampelHDAdherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid studyOphthalmology2009116219119919084273
   PubMed Web of Science ®Google Scholar
• RichterAAntonSEKochPDennettSLThe impact of reducing dose frequency on health outcomesClin Ther20032582307233514512137
   PubMed Web of Science ®Google Scholar
• TsaiTRobinALSmithJP3rdAn evaluation of how glaucoma patients use topical medications: a pilot studyTrans Am Ophthalmol Soc2007105293318427591
   PubMedGoogle Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol2007144453354017686450
   PubMed Web of Science ®Google Scholar
• HeaneyLHicksWSeeruthunRAdherence in Asthma: Comparing Clinical Trials to the “Real World.”Pharmaceutical Product Development, LLC2013 Available from: http://www.ppdi.com/late-stage-asthma/Adherence-In-Asthma_PPD-White-Paper.pdfAccessed May 14, 2014
   Google Scholar
• IchimaruNKakutaYAbeTTreatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressantsTransplant Proc20084051362136518589106
   PubMed Web of Science ®Google Scholar
• HauberABHanSYangJCEffect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesPatient Prefer Adherence2013793794924086104
   PubMed Web of Science ®Google Scholar
• BockOFelsenbergDBiphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practiceClin Interventions Aging200832279297
   PubMed Web of Science ®Google Scholar